|
|
 |
|
Viewing report
|
|
|
|
2010 Chartbook of International Pharmaceutical Prices
Decision Resources, Inc., Aug 2010, Pages: 73
Payers in all countries are increasing their pressure on manufacturers to cut prices. But prescription drug pricing and reimbursement policies vary markedly among the leading pharmaceutical markets, so, to best determine pricing, pharmaceutical companies need to be aware of international price differentials. Many studies have compared retail prices in different countries, but international comparisons of pharmaceutical prices at the ex-manufacturer level are relatively uncommon. This chartbook - our seventh annual analysis of international drug prices - fills that need. This year, we have added coverage of three new product categories—pain therapies, vaccines, and miscellaneous other drugs—thereby expanding the scope of the study from 170 to 200 of the world’s best-selling drugs. The report features 39 data-rich tables and figures that provide price comparisons in seven major markets and by select therapeutic area.
Questions Answered in this Report:
In 2009, European prescription drug prices averaged just 56% of U.S. prices. How did prices vary among the five leading European markets? Which therapeutic areas had the highest and lowest prices relative to U.S. prices?
Japanese drug prices averaged 78% of U.S. prices in 2009. How many drugs were more expensive in Japan than in the United States? What impact will the most recent biennial price revision have on drug prices on Japan?
The percentage price differential between the United States and other leading pharmaceutical markets is generally much narrower for biologics than for small-molecule drugs. How do European and Japanese prices for monoclonal antibodies compare with prices in the United States? How great is the percentage price differential for recombinant proteins?
Payers in all markets will be looking to increase pressure on manufacturers to moderate prescription drug prices. How is U.S. healthcare reform likely to impact drug prices in the United States? What action is the European Parliament contemplating with regard to drug pricing? What methods are European governments using to control pharmaceutical prices? What changes has the Japanese government recently introduced?
Scope of the report:
Overall price differentials among markets: ex-manufacturer prices of 200 best-selling drugs in six major markets (France, Germany, Italy, Spain, United Kingdom, Japan) relative to U.S. prices.
Pricing hierarchy in individual markets: U.S. price of each of the 200 drugs under review as a percentage of average prices in the six other markets under review; pricing hierarchy in individual European markets, Japan, and the fi ve European markets overall as a percentage of U.S. prices.
Price variations by therapeutic area: price variations among the 200 drugs in our analysis divided into 13 categories: cardiovascular drugs, metabolic disease therapies, immune and inflammatory disease therapies, infectious disease therapies, neurology drugs, psychiatric drugs, antineoplastic drugs, treatments for the side effects of chemotherapy, gastrointestinal drugs, genitourinary drugs, pain therapies, vaccines, miscellaneous other drugs.
Prices of biologics: prices as a percentage of U.S. prices for 33 biologics (10 monoclonal antibodies and 23 recombinant proteins) in the six other markets under study.
Outlook and implications: implications of U.S. healthcare reform for drug prices in the United States; ongoing strict government control of drug prices in Europe; impact of the most recent pricing reforms in Japan.
Key Terms for this Report:
Pricing, Biologics, Cardiovascular drugs, Metabolic disease therapies, Immune and inflammatory disease therapies, infectious diseases, Neurology drugs, Psychiatric drugs, Antineoplastic drugs, Treatments for the side effects of chemotherapy, Gastrointestinal drugs, Genitourinary drugs, Pain therapies, Vaccines, Miscellaneous other drugs
Customers who bought this item also bought
Human Vaccines - Global Strategic Business Report
World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
Drug Delivery in Cancer - Technologies, Markets and Companies
Transdermal Drug Delivery - Technologies, Markets, and Companies
Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing
Pediatric Drugs and Vaccines - Global Strategic Business Report
Adult and Adolescent Vaccines Market to 2017 - Partnerships Increase as Licensing and Co-Development Account for 73% of all Deal-Making Activity in 2010
Seasonal Influenza Vaccine Market in Asia - Pacific Region - Threat of Pandemic Influenza and Increasing Vaccination Coverage to Drive Growth
Lung Cancer Vaccines: Pipeline, Strategies and Clinical
Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity
|
|
|
|
